Pfizer Grant for Generic JAK Inhibitors in Rheumatology 2026

🌟 About Pfizer Grant for Generic JAK Inhibitors in Rheumatology

This opportunity is designed to help healthcare professionals better understand how treatment pathways may change as generic JAK inhibitors enter the U.S. market in 2026, and how current evidence can inform safe, effective, and data-driven patient care.

Sponsor Organization:

• Pfizer

🎁 Benefits of Pfizer Grant for Generic JAK Inhibitors in Rheumatology

The grant provides:

• Up to $100,000 USD per project
• Maximum project duration: 12 months

✅ Eligibility Criteria

Intended Recipients:

This funding opportunity is intended for organizations, not individuals.

Examples of Eligible Applicants:

• Healthcare institutions
• Professional medical societies
• Medical education companies
• Other organizations involved in:
  • Healthcare education
  • Continuing medical education (CME/CE)
  • Quality improvement
  • Healthcare performance improvement

Core Eligibility Requirements:

To be eligible, the applicant organization should:

• Play a central role in the proposed project
• Be legally able to receive funding directly from Pfizer Inc.
• Be responsible for project delivery and oversight
• Have the organizational capacity to implement an independent educational initiative

📅 Application Date and Process

• Application Deadline: 21 May, 2026
• Applicants can click on the provided link to the application website to apply.

📄 Opportunity Application

For more details, view the official document for the Pfizer Grant for Generic JAK Inhibitors in Rheumatology.

This opportunity is a great chance for organizations involved in healthcare education and improvement to secure funding for impactful projects.

• Up to $100,000 USD per project
• Maximum project duration: 12 months